We used the transcriptomic and clinical data from melanoma and glioblastoma patients of anti-PD1 or anti-CTLA4 therapy to predict the immunotherapy response of cohorts with different STAT3/CDK2/4/6 expression. This evidence concerns the gene CTLA4 and glioblastoma.